Ilana Meyer is a member of Foley & Lardner’s Health Care Practice Group. She began at Foley as a summer associate. While in law school, she worked as a Judicial Intern for Senior Judge Paul L. Friedman of the United States District Court for the District of Columbia. Most recently, Ilana interned in the Office of General Counsel for the Dana-Farber Cancer Institute working on regulatory and policy issues. She also has experience within a multidisciplinary team, performing complex clinical ethics consultations.
Présentations et publications
- Co-auteur, "Massachusetts : New Year, New Law - Governor Signs "An Act enhancing the market review process" (House Bill No. 5159)," Health Care Law Today (14 janvier 2025)
- Co-auteur, "Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry", Health Care Law Today (5 août 2024)
- Co-author, “Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use,” Health Care Law Today (March 13, 2024)
Les avocats de Foley contribuent au manuel Representing Physicians de l'American Health Law Association (Association américaine du droit de la santé)
Les avocats de Foley & Lardner LLP Jana Kolarik, Claire Marblestone, Illana Meyer, Sheridan Organ et Kate Pamperin ont contribué à la cinquième édition du Representing Physician's Handbook de l'American Health Law Association (AHLA).
Massachusetts : nouvelle année, nouvelle loi — Le gouverneur signe « une loi visant à améliorer le processus d'examen du marché » (projet de loi n° 5159 de la Chambre des représentants).
Le 8 janvier 2025, la gouverneure Maura Healey a promulgué la loi H.B. 5159, « une loi visant à améliorer le processus d'examen du marché ».
Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry
The Massachusetts legislative session officially closed on August 1, 2024 after an unusual half day extension.
What Does the End of Chevron Deference Mean for Federal Health Care Programs?
On June 28, 2024, the Supreme Court rejected the doctrine of Chevron deference in the closely watched case of Loper Bright Enterprises v. Raimondo.
Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use
In February 2024, the U.S. Food and Drug Administration published its finalized guidance concerning its investigational drug charging regulations.